Cerevance is a drug discovery company advancing treatments for brain diseases. The company’s lead program, Cerevance has 5 compounds under development.. The aim of development for CVN293 is to treat neuroinflammation in ALS and Alzheimer’s disease. Craig Thompson is the current CEO.